|
Patent landscape, scope, and claims: |
United States Patent 7,560,429: Scope, Claims, and Competitive Landscape
United States Patent 7,560,429 claims an orodispersible solid (ODF) desmopressin acetate product with three hard constraints: (i) mouth disintegration within 10 seconds, (ii) desmopressin content specified as “free base” at 25 μg, 50 μg, or 75 μg, and (iii) an open matrix carrier architecture (gelatin-based) and a specific manufacturing approach using solvent sublimation (including freeze-drying) from a molded solid-state composition. The claims extend beyond the product into a process and treatment methods, and into packaged formats with patient instructions.
What is the core claim architecture?
What limitations define claim scope for the product (claims 1–5 and 10–11)?
The claims converge on a single product concept with three gating limitations:
| Limitation |
How it appears |
Practical meaning for design-around |
| Orodispersible disintegration |
“disintegrates in the mouth within 10 seconds” (claims 1, 10, 11, 15) |
Any alternative with a disintegration time >10 seconds avoids literal infringement for that limitation. |
| Dose strength and reference basis |
“amount of desmopressin, measured as the free base, selected from … 25 μg, 50 μg and 75 μg” (claims 1, 10, 11, 15) |
Only those three strengths are explicitly covered; other dose strengths are outside literal scope (subject to doctrine-of-equivalents risk). |
| Matrix and carrier identity |
“open matrix network … water-soluble or water-dispersible carrier … inert towards desmopressin acetate” (claim 2); then “open matrix network comprises gelatin” (claim 3) and “fish gelatin” (claim 4), “non-gelling” (claim 5) |
The carrier architecture is tightly specified. To avoid claim 2–5, an accused product can use a different carrier class or matrix design that does not meet the “open matrix network” requirement as construed in the patent context. |
How does the patent treat dose measurement and formulation identity?
Two features are unusually specific for freedom-to-operate work:
- Desmopressin content is expressed as “free base.” The claims lock the dose reference to free base equivalence, not salt mass alone (claims 1, 10, 11, 15).
- Carrier performance is defined by inertness and dispersion behavior. Claim 2 requires a “water-soluble or water-dispersible carrier material” that is “inert towards desmopressin acetate,” narrowing carrier options.
How broad is the process coverage (claims 6–9, 13–14, 15–19)?
What is the manufacturing method that anchors process claims (claims 6–9)?
Claim 6 claims a process with these hard elements:
- Start composition: desmopressin acetate + a solution of carrier material in the solvent.
- Solid-state in a mold: “composition is in the solid state in a mold.”
- Key step: “subliming solvent” from the composition.
- Product characteristics in end result: the resulting ODF must disintegrate in the mouth within 10 seconds and contain desmopressin free base at 25/50/75 μg.
Claims 7–9 add narrower specifics:
- Claim 7: sublimation carried out by freeze drying.
- Claim 8: solvent is water.
- Claim 9: solution pH 3 to 6.
Claims 13–14 further tighten pH bands:
- Claim 13: pH 3.5 to 5.5.
- Claim 14: pH 4 to 5.
Does the patent cover the process only when it yields the exact ODF profile?
Yes. The process claims are drafted as process + product-by-structure/product-by-result constraints. Claim 6 and dependent claims require the produced dosage form to meet the same disintegration and free-base dose limitations. That linkage narrows enforcement because an accused process must not only use sublimation from a molded solid-state carrier solution, it must also yield an ODF with the claimed performance and dose.
Is there overlap between product process claims (claims 15–19) and method claims (claims 6–14)?
Claim 15 functions like a product claim plus a process manufacturing qualifier:
- (i) disintegrates within 10 seconds,
- (ii) contains desmopressin free base 25/50/75 μg,
- (iii) is prepared by subliming solvent from desmopressin acetate + carrier solution in solvent, with the composition in the solid state in a mold.
Then claims 16–19 parallel claims 7–9 and 13–14:
- Claim 16: freeze drying
- Claim 17: water solvent
- Claim 18: pH 3 to 6
- Claim 19: pH 4 to 5
Practically, this creates a second enforcement handle: a product sold may be captured as “prepared by” the claimed process. That matters when evidence of process history is obtainable through documentation or manufacturing disclosures.
How do treatment and packaging claims expand enforcement (claims 10–12)?
What do the method-of-treatment claims require (claim 10)?
Claim 10 requires:
- treating incontinence, PNE, nocturia, or central diabetes insipidus; and
- administering an effective generally non-toxic amount of desmopressin acetate; and
- the administration uses an ODF that meets:
- disintegration within 10 seconds
- dose strength in free base 25/50/75 μg
This is a classic method claim tethered to a specific formulation performance and dosing band.
What do the packaging and instructions claims add (claims 11–12)?
Claim 11 adds a packaged format:
- packaged ODF with disintegration within 10 seconds,
- desmopressin free base 25/50/75 μg,
- plus instructions “to place the dosage form in a subject’s mouth.”
Claim 12 claims a method of preparing the packaged dosage form by bringing into association the ODF and the instructions.
These claims can be used to enforce distribution formats, especially if the formulation is otherwise argued not to infringe a pure product claim but is still sold with qualifying instructions and packaging.
Claim-by-claim scope map (direct reading)
What does each claim cover in enforceable terms?
| Claim |
Category |
Key limitations (only hard scope constraints) |
| 1 |
Product |
ODF disintegrates in mouth within 10 seconds; desmopressin acetate; amount of desmopressin as free base is 25/50/75 μg |
| 2 |
Product (dependent) |
Open matrix network; water-soluble/dispersible carrier inert to desmopressin acetate |
| 3 |
Product (dependent) |
Open matrix network comprises gelatin |
| 4 |
Product (dependent) |
Gelatin is fish gelatin |
| 5 |
Product (dependent) |
Fish gelatin is non-gelling |
| 6 |
Process |
Subliming solvent from composition containing desmopressin acetate and carrier-material solution; composition is solid in mold; results in ODF disintegrating <10 sec and containing free-base 25/50/75 μg |
| 7 |
Process (dependent) |
Subliming is freeze drying |
| 8 |
Process (dependent) |
Solvent is water |
| 9 |
Process (dependent) |
Solution pH 3 to 6 |
| 10 |
Method of treatment |
Treats incontinence/PNE/nocturia/central DI; administer desmopressin acetate in the qualifying ODF format and dose (disintegrates <10 sec; free-base 25/50/75 μg) |
| 11 |
Packaged product |
Packaged ODF with qualifying performance/dose plus instructions to place in mouth |
| 12 |
Packaging process |
Bringing into association qualifying ODF and instructions for placing in mouth |
| 13 |
Process (dependent) |
pH 3.5 to 5.5 |
| 14 |
Process (dependent) |
pH 4 to 5 |
| 15 |
Product (method-qualified) |
ODF prepared by subliming solvent from desmopressin + carrier solution in solvent; composition solid in mold; disintegrates <10 sec; free-base 25/50/75 μg |
| 16 |
Product (dependent) |
subliming is freeze drying |
| 17 |
Product (dependent) |
solvent is water |
| 18 |
Product (dependent) |
pH 3 to 6 |
| 19 |
Product (dependent) |
pH 4 to 5 |
Practical design-around vectors mapped to claim language
Where can competitors realistically avoid the claims based on literal text?
The claims are structured so that a single failed limitation can move an accused product outside literal scope.
| Design variable |
Claim elements implicated |
Literal “escape” path based on wording |
| Disintegration time |
“within 10 seconds” (claims 1, 10, 11, 15) |
Use an ODF that disintegrates in >10 sec under the patent’s relevant test conditions (test method matters, but the threshold is explicit). |
| Dose strength |
“25/50/75 μg” (claims 1, 10, 11, 15) |
Offer strengths outside those three values (or combine with formulation changes to weaken equivalence arguments). |
| Carrier class |
“open matrix network … water-soluble or water-dispersible carrier… inert” (claim 2) and “comprises gelatin” (claim 3) and “fish gelatin” (claim 4) and “non-gelling” (claim 5) |
Replace gelatin/fish gelatin/non-gelling system and avoid meeting the open-matrix definition as construed. |
| Solvent sublimation from molded solid |
“subliming solvent … composition in the solid state in a mold” (claims 6, 15) |
Use a fundamentally different manufacturing route that does not involve sublimation from a molded solid-state composition with a carrier solution in solvent. |
| Freeze-drying and water solvent |
“freeze drying” (claims 7, 16) and “solvent is water” (claims 8, 17) |
If solvent is not water or the process is not freeze-drying, avoid the dependent claims; independent claims may still be at issue unless sublimation itself is avoided. |
| pH window |
pH 3 to 6 (claims 9, 18) and 3.5 to 5.5 (claim 13) and 4 to 5 (claim 14, 19) |
Adjust pH outside 3 to 6 (for the dependent claims) while still preserving product performance; however, independent “subliming solvent” claims remain broader. |
Patent landscape: what this claim set implies for competitive freedom-to-operate
What is the competitive “zone” occupied by 7,560,429?
Based on claim structure, the patent occupies a zone where all of the following are true:
- Route: ODF desmopressin acetate is manufactured via solvent sublimation (including freeze-drying), starting from a desmopressin + carrier-material solution system cast or molded as a solid-state composition.
- Matrix architecture: uses an open matrix network with fish gelatin that is non-gelling and inertness requirements.
- Performance: disintegrates in mouth within 10 seconds.
- Dose band: 25/50/75 μg free-base equivalent.
That combination narrows the set of plausible competing product concepts relative to the broader universe of ODFs.
What is the likely enforcement posture?
The claim set supports multiple litigation hooks:
- Product infringement against ODFs that meet disintegration and dose constraints (claims 1 and 10).
- Carrier-identity enforcement where gelatin/fish gelatin/non-gelling is used (claims 2–5).
- Process-qualified product enforcement where manufacturing history is provable (claims 15–19).
- Distribution and labeling enforcement for packaged products with “instructions to place” (claims 11–12).
- Method-of-use enforcement for branded or trial data where administration is tied to the qualifying ODF (claim 10).
Key takeaways
- 7,560,429 is tightly framed around a specific ODF profile: mouth disintegration within 10 seconds plus desmopressin free-base content at 25/50/75 μg.
- Carrier architecture is a major narrowing limiter: “open matrix network” with gelatin = fish gelatin = non-gelling (claims 2–5).
- Manufacturing route is a second major limiter: solvent sublimation from a molded solid-state composition, with freeze-drying and water solvent plus specific pH bands added in dependent claims (claims 6–9, 13–14, 15–19).
- Enforcement extends beyond the molecule to product formats and treatment via packaging instructions (claims 11–12) and use in specific indications (claim 10).
- Design-around leverage is strongest where a competitor can change at least one gating element: disintegration threshold, dose band, fish gelatin non-gelling carrier system, or the sublimation-from-mold manufacturing route.
FAQs
-
Does 7,560,429 cover all desmopressin acetate ODFs?
No. Coverage is limited to ODFs that disintegrate in the mouth within 10 seconds and contain desmopressin free base at 25/50/75 μg, with additional narrowing in dependent claims to fish gelatin non-gelling open matrix.
-
What is the most decisive formulation limitation for literal infringement?
The “disintegrates in the mouth within 10 seconds” limitation coupled with the exact free-base dose band (25/50/75 μg).
-
Is the patent’s carrier requirement limited to gelatin?
Dependent claims do. Claim 2 requires an open matrix network with a specified inert, water-soluble/dispersible carrier; claims 3–5 specify gelatin then fish gelatin then non-gelling fish gelatin.
-
Can a competitor avoid process claims by using freeze-drying but a different pH?
Dependent claims include pH ranges (claims 9, 13, 14, 18, 19). Changing pH outside those windows can avoid those dependents, but broader process/product-qualified limitations still remain.
-
Do packaging claims matter if the product formulation is identical?
Yes. Claims 11–12 add a packaging/instructions component requiring the qualifying ODF plus instructions to place in the mouth.
References
[1] United States Patent Application Publication / Patent No. 7,560,429 (claims as provided in the prompt text).
More… ↓
⤷ Start Trial
|
